Business registration in 2 seconds: digitalization of the economy https://ymaho.com/business-registration-in-2-seconds-digitalization-of-the-economy
Learn how automation of government services reduced business registration to mere moments. We analyze its impact on the market, taxes, and global digitalization trends.
Gene therapy without registration: Russia legalizes bespoke drugs https://ymaho.com/gene-therapy-without-registration-russia-legalizes-bespoke-drugs
Russia will allow individual gene therapy for orphan diseases without state registration. A chance for children with deadly mutations. Learn how it works.
How to get cashback for travel with the Mir card: instructions 2026 https://ymaho.com/how-to-get-cashback-for-travel-with-the-mir-card-instructions-2026
Step-by-step guide: registration in Privet, Mir, promotion terms, partner list, and limits up to 22,000 RUB. Learn how to get 20% back on hotels and tours.
FDA agreed on trial design for Privosegtor in optic neuritis https://ymaho.com/fda-agreed-on-trial-design-for-privosegtor-in-optic-neuritis
FDA approved the design of registration trials for the neuroprotector Privosegtor for the treatment of optic neuritis. Learn how the drug can change neuro-ophthalmology and what prospects the SPA agreement opens.
Unemployment benefit: how to apply through the employment center https://ymaho.com/unemployment-benefit-how-to-apply-through-the-employment-center
Step-by-step instructions for applying for unemployment benefits through Rabota Rossii. Payment amounts in 2025, documents, re-registration. Learn how to get up to 137 USD.
Zosurabalpin Roche: new antibiotic against superbug https://ymaho.com/zosurabalpin-roche-new-antibiotic-against-superbug
Antibiotic zosurabalpin from Roche is effective against resistant Acinetobacter baumannii (CRAB). Learn how it works and when registration is expected. Read details.
CRISPR therapy in vivo: Intellia study 87% efficacy in HAE https://ymaho.com/crispr-therapy-in-vivo-intellia-study-87-efficacy-in-hae
Phase 3 HAELO: single CRISPR infusion reduced hereditary angioedema attacks by 87% vs placebo. First in vivo therapy on the verge of registration. Details, insights, forecasts.